165 related articles for article (PubMed ID: 30108440)
1. Lobaplatin-based regimens outperform cisplatin for metastatic breast cancer after anthracyclines and taxanes treatment.
Wang Z; Xu L; Wang H; Li Z; Lu L; Li X; Zhang Q
Saudi J Biol Sci; 2018 Jul; 25(5):909-916. PubMed ID: 30108440
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of biweekly vinorelbine and oxaliplatin in second- or third-line metastatic triple-negative breast cancer.
Zhang J; Wang L; Wang Z; Hu X; Wang B; Cao J; Lv F; Zhen C; Zhang S; Shao Z
Cancer Biol Ther; 2015; 16(2):225-32. PubMed ID: 25648299
[TBL] [Abstract][Full Text] [Related]
3. Vinorelbine and cisplatin in metastatic breast cancer patients previously treated with anthracyclines.
Vassilomanolakis M; Koumakis G; Barbounis V; Demiri M; Pateras H; Efremidis AP
Ann Oncol; 2000 Sep; 11(9):1155-60. PubMed ID: 11061611
[TBL] [Abstract][Full Text] [Related]
4. Vinorelbine and cisplatin for metastatic breast cancer: a salvage regimen in patients progressing after docetaxel and anthracycline treatment.
Vassilomanolakis M; Koumakis G; Demiri M; Missitzis J; Barbounis V; Efremidis AP
Cancer Invest; 2003; 21(4):497-504. PubMed ID: 14533438
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy and toxicity of vinorelbine (NVB)-based regimens in patients with metastatic triple negative breast cancer (mTNBC) pretreated with anthracyclines and taxanes].
Du F; Yuan P; Luo Y; Wang J; Ma F; Cai R; Fan Y; Li Q; Zhang P; Xu B
Zhonghua Zhong Liu Za Zhi; 2015 Oct; 37(10):788-92. PubMed ID: 26813602
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of lipoplatin (liposomal cisplatin)/vinorelbine combination in HER-2/neu-negative metastatic breast cancer.
Farhat FS; Temraz S; Kattan J; Ibrahim K; Bitar N; Haddad N; Jalloul R; Hatoum HA; Nsouli G; Shamseddine AI
Clin Breast Cancer; 2011 Dec; 11(6):384-9. PubMed ID: 21993011
[TBL] [Abstract][Full Text] [Related]
7. Effective treatment of advanced breast cancer with vinorelbine, mitomycin C plus human granulocyte colony-stimulating factor.
Kornek GV; Haider K; Kwasny W; Hejna M; Raderer M; Meghdadi S; Burger D; Schneeweiss B; Depisch D; Scheithauer W
Br J Cancer; 1996 Nov; 74(10):1668-73. PubMed ID: 8932353
[TBL] [Abstract][Full Text] [Related]
8. Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer.
Chen XL; Du F; Hong RX; Wang JY; Luo Y; Li Q; Fan Y; Xu BH
Chin J Cancer; 2016 Apr; 35():39. PubMed ID: 27112139
[TBL] [Abstract][Full Text] [Related]
9. A Randomized Controlled Trial Comparing Clinical Outcomes and Toxicity of Lobaplatin- Versus Cisplatin-Based Concurrent Chemotherapy Plus Radiotherapy and High-Dose-Rate Brachytherapy for FIGO Stage II and III Cervical Cancer.
Wang JQ; Wang T; Shi F; Yang YY; Su J; Chai YL; Liu Z
Asian Pac J Cancer Prev; 2015; 16(14):5957-61. PubMed ID: 26320479
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of palliative weekly low-dose gemcitabine-Cisplatin chemotherapy in anthracycline- and taxane- pretreated metastatic breast cancer patients.
Kim JS; Park IH; Lee KS; Ro J
J Breast Cancer; 2014 Dec; 17(4):339-43. PubMed ID: 25548581
[TBL] [Abstract][Full Text] [Related]
11. Retrospective study of the efficacy and toxicity of lobaplatin in combined chemotherapy for metastatic breast cancer.
Wu Y; Xu XY; Yan F; Sun WL; Zhang Y; Liu DL; Shen B
Onco Targets Ther; 2019; 12():4849-4857. PubMed ID: 31417282
[TBL] [Abstract][Full Text] [Related]
12. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
13. Vinorelbine, cisplatin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients: a phase II study.
Nolè F; Munzone E; Mandalà M; Catania C; Orlando L; Zampino MG; Minchella I; Colleoni M; Peruzzotti G; Marrocco E; Goldhirsch A
Ann Oncol; 2001 Jan; 12(1):95-100. PubMed ID: 11249057
[TBL] [Abstract][Full Text] [Related]
14. [Effects and toxicity of neoadjuvant chemotherapy with vinorelbine and cisplatin in treatment of operable breast cancer previously non-responsive to anthracyclines and taxanes-containing regimen: analysis of 19 cases].
Xu L; Ye JM; Zhao JX; Duan XN; Liu YH
Zhonghua Yi Xue Za Zhi; 2009 Mar; 89(10):683-5. PubMed ID: 19595063
[TBL] [Abstract][Full Text] [Related]
15. Capecitabine/cisplatin doublet in anthracycline and taxane pretreated and HER-2 negative metastatic breast carcinoma patients.
Ozdemir N; Aksoy S; Sendur MA; Akinci MB; Yazici O; Budakoglu B; Abali H; Oksuzoglu B; Zengin N
J BUON; 2013; 18(4):831-7. PubMed ID: 24344005
[TBL] [Abstract][Full Text] [Related]
16. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.
Farhat F; Kattan JG; Ghosn M
Cancer Chemother Pharmacol; 2016 May; 77(5):1069-77. PubMed ID: 27059339
[TBL] [Abstract][Full Text] [Related]
17. Taxane-containing regimens for metastatic breast cancer.
Ghersi D; Willson ML; Chan MM; Simes J; Donoghue E; Wilcken N
Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD003366. PubMed ID: 26058962
[TBL] [Abstract][Full Text] [Related]
18. Dynamic contrast-enhanced MRI to predict response to vinorelbine-cisplatin alone or with rh-endostatin in patients with non-small cell lung cancer and bone metastases: a randomised, double-blind, placebo-controlled trial.
Zhang R; Wang ZY; Li YH; Lu YH; Wang S; Yu WX; Zhao H
Lancet; 2016 Oct; 388 Suppl 1():S95. PubMed ID: 27968915
[TBL] [Abstract][Full Text] [Related]
19. Clinical comparative investigation of efficacy and toxicity of cisplatin plus gemcitabine or plus Abraxane as first-line chemotherapy for stage III/IV non-small-cell lung cancer.
Ai D; Guan Y; Liu XJ; Zhang CF; Wang P; Liang HL; Guo QS
Onco Targets Ther; 2016; 9():5693-5698. PubMed ID: 27695347
[TBL] [Abstract][Full Text] [Related]
20. Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial.
Yuan P; Hu X; Sun T; Li W; Zhang Q; Cui S; Cheng Y; Ouyang Q; Wang X; Chen Z; Hiraiwa M; Saito K; Funasaka S; Xu B
Eur J Cancer; 2019 May; 112():57-65. PubMed ID: 30928806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
